CEACAM5 and pancreatic neoplasm: As prostaglandin E2 can shape an immunosuppressive barrier in the tumour microenvironment [34], the prostanoid metabolic process is likely to promote the immune resistance of CEACAM5+ stemness-high pancreatic cancers.